Trial Profile
A Multicenter, Non-randomized, Open Label Study to Evaluate the Efficacy and Security of Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 12 Dec 2023 Results deriving blood samples from 28 patients , assessing the T cell immune profile of ibrutinib-treated CLL patients, and identifying potential adaptive mechanisms to BTK inhibition in B cells in the first 12 months of continuous treatment, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Sep 2022 Planned End Date changed from 1 May 2022 to 1 Sep 2022.
- 19 May 2020 Planned End Date changed from 1 Oct 2020 to 1 May 2022.